An Open-Label Phase 1 Study to Investigate the Pharmacokinetics of Aldoxorubicin (INNO-206; DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2014
At a glance
- Drugs Aldoxorubicin (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors CytRx Corporation
- 03 Jun 2014 Interim results (n=10) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 13 Aug 2013 Planned End Date changed from 1 Aug 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 21 May 2013 Initial results reported in a CytRx media release.